Literature DB >> 2245460

Ovarian steroid levels in migraine with and without aura.

S Nagel-Leiby1, K M Welch, S Grunfeld, G D'Andrea.   

Abstract

Radioimmunoassays were used to measure interictal levels of ovarian steroids (oestradiol, total oestrogens and progesterone) in migraine patients at the onset of menses and coincident with the luteinizing hormone surge preceding ovulation. Results of these verified biochemically-contrasting points of the ovarian cycle were used to compare 13 migraine patients without aura and 6 migraine patients with aura with 17 non-migraine women. No group differences were found for physiological basal levels of ovarian steroids measured at menses. Preceding ovulation elevation in oestradiol levels relative to normal was found in migraine patients with aura but not in migraine patients without aura. These results suggest that a variation in oestradiol levels is an important factor in the different clinical expressions of migraine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245460     DOI: 10.1046/j.1468-2982.1990.1003147.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

Review 1.  Biochemistry of primary headaches: role of tyrosine and tryptophan metabolism.

Authors:  G D'Andrea; S Cevoli; D Colavito; A Leon
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

Review 2.  Pharmacological targeting of spreading depression in migraine.

Authors:  Katharina Eikermann-Haerter; Anil Can; Cenk Ayata
Journal:  Expert Rev Neurother       Date:  2012-03       Impact factor: 4.618

3.  Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.

Authors:  Megan S Rice; Pamela M Rist; Anke C Winter; Tobias Kurth; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2017-10-30       Impact factor: 7.396

4.  Migraine and breast cancer risk: a prospective cohort study and meta-analysis.

Authors:  Anke C Winter; Megan S Rice; Renée T Fortner; A Heather Eliassen; Tobias Kurth; Rulla M Tamimi
Journal:  J Natl Cancer Inst       Date:  2014-12-12       Impact factor: 13.506

5.  Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1.

Authors:  Katharina Eikermann-Haerter; Ergin Dileköz; Chiho Kudo; Sean I Savitz; Christian Waeber; Michael J Baum; Michel D Ferrari; Arn M J M van den Maagdenberg; Michael A Moskowitz; Cenk Ayata
Journal:  J Clin Invest       Date:  2008-12-22       Impact factor: 14.808

6.  The association of migraine with menstrually related mood disorders and childhood sexual abuse.

Authors:  Adomas Bunevicius; David R Rubinow; Anne Calhoun; Jane Leserman; Erin Richardson; Kim Rozanski; Susan S Girdler
Journal:  J Womens Health (Larchmt)       Date:  2013-08-09       Impact factor: 2.681

Review 7.  Sex and the migraine brain.

Authors:  D Borsook; N Erpelding; A Lebel; C Linnman; R Veggeberg; P E Grant; C Buettner; L Becerra; R Burstein
Journal:  Neurobiol Dis       Date:  2014-03-21       Impact factor: 5.996

Review 8.  [Migraine and hormones: what can we be certain of?].

Authors:  U Bingel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

9.  Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model.

Authors:  Pernille Bøttger; Simon Glerup; Bodil Gesslein; Nina B Illarionova; Toke J Isaksen; Anders Heuck; Bettina H Clausen; Ernst-Martin Füchtbauer; Jan B Gramsbergen; Eli Gunnarson; Anita Aperia; Martin Lauritzen; Kate L Lambertsen; Poul Nissen; Karin Lykke-Hartmann
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

Review 10.  Cortical spreading depression as a target for anti-migraine agents.

Authors:  Cinzia Costa; Alessandro Tozzi; Innocenzo Rainero; Letizia Maria Cupini; Paolo Calabresi; Cenk Ayata; Paola Sarchielli
Journal:  J Headache Pain       Date:  2013-07-23       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.